Navigation Links
Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
Date:10/7/2010

SUNNYVALE, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Cepheid today announced that it will report financial results for its third quarter ended September 30, 2010, on Thursday, October 21, 2010, after the close of the market.

The company will host a management presentation at 2 p.m. Pacific Time on Thursday, October 21, 2010, to discuss the results.  To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

Interested participants and investors may also listen to the live teleconference call by dialing (866) 788-0538 (domestic) or (857) 350 1676 (international), and entering participant code 51795047.  A replay will be available for seven days beginning at 4 p.m. Pacific Time.  Access numbers for this replay are (888) 286-8010 (domestic) and (617) 801-6888 (international), with passcode 72854495.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets.  The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.  The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges.  Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.  See http://www.cepheid.com for more information.CONTACTS:For Media Inquiries:For Investor Inquiries:Jared TiptonJacquie RossCepheid Corporate CommunicationsCepheid Investor RelationsTel: (408) 400 8377Tel: (408) 400 8329jared.tipton@cepheid.cominvestor.relations@cepheid.com
'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
3. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
4. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
5. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
6. Cepheid Reports 2009 First Quarter Results
7. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
8. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
9. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
10. Cepheid to Webcast Upcoming Financial Presentations
11. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):